CARVEDILOLO E’ EFFICACE ANCHE NELLE PRIME FASI DELL’ASCITE, PRIMA DELLA COMPARSA DI VARICI AD ALTO RISCHIO ! IL TRIAL CARVE-AS DA “AJG”

ENDOSCOPIA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER

Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial) Khajuria, Rahul et al. for the CARVE-AS trial _______________________________________________________ KEY POINTS FROM IA Il CARVE-AS trial apre una nuova prospettiva nella gestione della cirrosi: il carvedilolo potrebbe essere utile già nelle fasi iniziali dell’ascite, prima della comparsa…

REPORT DA DDW 2026 (2-5 MAGGIO). I 3 PAPER PIU’ INTERESSANTI SECONDO D.A.JOHNSON. ED ANCHE PER NOI. DA”MEDSCAPE” (FREE)

EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA DEI PROBIOTICI

Digestive Disease Week (DDW) 2026 Highlights: Part 2 David A. Johnson, MD Professor of medicine and chief of gastroenterology at Eastern Virginia Medical School/Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, Virginia.  Spontaneous Bacterial Peritonitis (SBP) Care Shows Gaps In 2021, the American Association for the Study of Liver Diseases…

AGONISTI DEI RECETTORI DEL GLUCAGONE GLP-1. CARE AMICHE ED AMICI E’ TEMPO CHE IMPARIAMO A PRESCRIVERLI NOI. UN’OTTIMA REVIEW DA “The New England Journal of Medicine” (FREE)

EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, NEWSLETTER, NUTRIZIONE

GLP-1 Receptor Agonists Clifford J. Rosen, M.D.,and Julie R. Ingelfinger, M.D. Summary Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric…

ESOFAGITE EOSINOFILA: BIOLOGICI VS STEROIDI. UNA GRANDE NETWORK META-ANALISI! DA “Clinical Gastroenterology and Hepatology”

ENDOSCOPIA, GASTROENTEROLOGIA, NEWSLETTER, NUTRIZIONE

Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients With Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis With Meta-Regression Mohammad Al Hayek et al. Abstract Background & Aims The therapeutic hierarchy of current pharmacologic options for eosinophilic esophagitis (EoE) has not been established. We performed a network meta-analysis to evaluate the comparative efficacy…

DARAXONRASIB E K PANCREAS. IL TRIAL RASolute 302 NEL COMMENTO DI VINAY PRASAD. UTILE COMMENTO !

CHIRURGIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI

Forwarded this email? Subscribe here for more Daraxonrasib in pancreas cancer. Vinay Prasad May 31 READ IN APP RASolute 302 trial has rightly generated significant excitement at ASCO2026 and I share this excitement. Pancreatic cancer has for long been a challenge for oncologists and KRAS is the classic ‘undruggable’ target. Any advance here is notable and must…

DARAXONRASIB E K PANCREAS: NEL TRIAL RASolute 302 MOSTRA EFFICACIA NEI PAZIENTI GIA’ TRATTATI. LA PLATEA ASCO IN PIEDI PER UNA STANDING OVATION. IN CONTEMPORANEA CON “NEJM” (FREE)

CHIRURGIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI, Senza categoria

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer Brian M. Wolpin et al. for the RMC-6236-001 Investigators Abstract Background Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate–bound mutant and wild-type RAS.…